Overview

Irbesartan in Hypertension

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

Study objectives: - To demonstrate the effect of irbesartan on the regulation of diastolic blood pressure, in case of missing one dose after a period of administration for 6 to 8 weeks - To evaluate the safety of irbesartan

Phase:

Phase 4

Details

Lead Sponsor:

Sanofi

Collaborator:

Bristol-Myers Squibb

Treatments:

Irbesartan